ArticleWorld journal of gastroenterology2014
Treatment of rectal cancer by transanal endoscopic microsurgery: experience with 425 patients.
Article in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 5 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Risk of recurrence after local resection of T1 rectal cancer: a meta-analysis with meta-regression.Surgical endoscopy · 2022Pooled it
- Towards personalized treatment of T2N0 rectal cancer: A systematic review of long-term oncological outcomes of neoadjuvant therapy followed by local excision.Journal of gastroenterology and hepatology · 2022Pooled it
- Local recurrence after local excision of early rectal cancer: a meta-analysis of completion TME, adjuvant (chemo)radiation, or no additional treatment.The British journal of surgery · 2020Pooled it
- Executive Summary of the American Radium Society Appropriate Use Criteria for Local Excision in Rectal Cancer.International journal of radiation oncology, biology, physics · 2019Guideline
- Individual participant data pooled-analysis of risk factors for recurrence after neoadjuvant radiotherapy and transanal local excision of rectal cancer: the PARTTLE study.Techniques in coloproctology · 2019Pooled it
- Brief insight regarding the use of transanal, laparoscopic, and robotic total mesorectal excision for rectal cancer.World journal of gastrointestinal surgery · 2025Article
- Local Recurrence of Premalignant and Early Malignant Rectal Polyps Treated by TEM-A Single-Center Experience.Journal of clinical medicine · 2024Article
- Local excision for middle-low rectal cancer after neoadjuvant chemoradiation: A retrospective study from a single tertiary center.World journal of gastrointestinal oncology · 2024Article
- Risk Factors for Rectal Cancer Recurrence after Local Excision of T1 Lesions from a Decade-Long Multicenter Retrospective Study.Journal of clinical medicine · 2024Article
- Comparing advanced platforms for local excision of rectal lesions.Surgical endoscopy · 2024Article
- Completion Surgery after Non-Curative Local Resection of Early Rectal Cancer.Visceral medicine · 2024Review
- Removal of a large rectal polyp with endoscopic submucosal dissection-trans-anal rectoscopic assisted minimally invasive surgery hybrid technique: A case report.World journal of gastrointestinal surgery · 2023Article
- Pattern of Residual Submucosal Involvement after Neoadjuvant Therapy for Rectal Cancer: A Rationale for the Utility of Endoscopic Submucosal Resection.Medicina (Kaunas, Lithuania) · 2023Review
- The Role of Local Excision after Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Different Perspective.Clinics in colon and rectal surgery · 2023Article
- Transanal endoscopic microsurgical submucosal dissection (TEM-ESD) for rectal adenomas: a retrospective cohort study of 145 consecutive cases.Langenbeck's archives of surgery · 2022Article
- The Role of Transanal Endoscopic Surgery for Early Rectal Cancer.Clinics in colon and rectal surgery · 2022Review
- Prognosis of Patients Over 60 Years Old With Early Rectal Cancer Undergoing Transanal Endoscopic Microsurgery - A Single-Center Experience.Frontiers in oncology · 2022Article
- A Meta-analysis of Transanal Endoscopic Microsurgery versus Total Mesorectal Excision in the Treatment of Rectal Cancer.Surgery journal (New York, N.Y.) · 2021Review
- Evolution of Transanal Total Mesorectal Excision.Clinics in colon and rectal surgery · 2020Review
- Local excision following chemoradiotherapy in T2-T3 rectal cancer: current status and critical appraisal.Updates in surgery · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo describe our experience in treating rectal cancer by transanal endoscopic microsurgery (TEM), report morbidity and mortality and oncological outcome.
methodsA total of 425 patients with rectal cancer (120 T1, 185 T2, 120 T3 lesions) were staged by digital rectal examination, rectoscopy, transanal endosonography, magnetic resonance imaging and/or computed tomography. Patients with T1-N0 lesions and favourable histological features underwent TEM immediately. Patients with preoperative stage T2-T3-N0 underwent preoperative high-dose radiotherapy; from 1997 those aged less than 70 years and in good general health also underwent preoperative chemotherapy. Patients with T2-T3-N0 lesions were restaged 30 d after radiotherapy and were then operated on 40-50 d after neoadjuvant therapy. The instrumentation designed by Buess was used for all procedures.
resultsThere were neither perioperative mortality nor intraoperative complications. Conversion to other surgical procedures was never required. Major complications (urethral lesions, perianal or retroperitoneal phlegmon and rectovaginal fistula) occurred in six (1.4%) patients and minor complications (partial suture line dehiscence, stool incontinence and rectal haemorrhage) in 42 (9.9%). Postoperative pain was minimal. Definitive histological examination of the 425 malignant lesions showed 80 (18.8%) pT0, 153 (36%) pT1, 151 (35.5%) pT2, and 41 (9.6%) pT3 lesions. Eighteen (4.2%) patients (ten pT2 and eight pT3) had a local recurrence and 16 (3.8%) had distant metastasis. Cancer-specific survival rates at the end of follow-up were 100% for pT1 patients (253 mo), 93% for pT2 patients (255 mo) and 89% for pT3 patients (239 mo).
conclusionTEM is a safe and effective procedure to treat rectal cancer in selected patients without evidence of nodal involvement. T2-T3 lesions require preoperative neoadjuvant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.